Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Ishihara N, Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Matsuura T, Tada T, Kodama Y, Fukumoto T.
Ishihara N, et al. Among authors: yoshida t.
Anticancer Res. 2025 Jan;45(1):251-260. doi: 10.21873/anticanres.17412.
Anticancer Res. 2025.
PMID: 39740814